Good afternoon, ladies and gentlemen, and welcome to the Inovio first quarter 2024 financial results conference call. At this ...

Fintel reports that on May 14, 2024, Stephens & Co. initiated coverage of Inovio Pharmaceuticals (NasdaqCM:INO) with a ...

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals (INO – Research ...

Detailed price information for Inovalis REIT (INO-UN-T) from The Globe and Mail including charting and trades.

Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Detailed price information for Inovalis REIT (INO-UN-T) from The Globe and Mail including charting and trades.

Stephens raised the price target for the Inovio Pharmaceuticals Inc (NASDAQ:INO) stock to “an Overweight”. The rating was released on May 14, 2024, according to finviz. The stock was downgraded by ...

Explore key financial outcomes and strategic updates from Inovio Pharmaceuticals Inc's first quarter of 2024, signaling robust progress and operational efficiency.

On a per-share basis, the Plymouth Meeting, Pennsylvania-based company said it had a loss of $1.31. The results missed Wall Street expectations. The average estimate of three analysts surveyed by ...

Good afternoon, ladies and gentlemen, and welcome to the INOVIO First Quarter 2024 Financial Results Conference Call. At this time all lines are in a listen-only mode. Following the presentation ...